Skip to main content
SpringerLink
Log in

A Brief Update on the Management of Hepatitis Delta

  • Invited Commentary
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chen H-Y, Shen D-T, Ji D-Z, Han P-C, Zhang W-M, Ma J-F, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018;18

  2. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997–1003.

    Article  CAS  Google Scholar 

  3. “Hepatitis D” World Health Organization, World Health Organization, July 2018, www.who.int/news-room/fact-sheets/detail/hepatitis-d.

  4. Casey RM, Dumolard L, Danovaro-Holliday MC, Gacic-Dobo M, Diallo MS, Hampton LM, et al. Global routine vaccination coverage, 2015. MMWR Morb Mortal Wkly Rep. 2016 Nov 18;65(45):1270–3.

    Article  Google Scholar 

  5. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994 Jan 13;330(2):88–94.

    Article  CAS  Google Scholar 

  6. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014 Jul 1;60(1):87–97.

    Article  CAS  Google Scholar 

  7. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167–74.

    Article  CAS  Google Scholar 

  8. Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2(12):877–89.

    Article  Google Scholar 

  9. Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13(10):580–9.

    Article  CAS  Google Scholar 

  10. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014 Jan;16(1):365.

    Article  Google Scholar 

  11. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int Off J Int Assoc Study Liver. 2011 Jan;31(1):7–21.

    Article  CAS  Google Scholar 

  12. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet Lond Engl. 2011 Jul 2;378(9785):73–85.

    Article  Google Scholar 

  13. Lin H-H, Lee SS-J, Yu M-L, Chang T-T, Su C-W, Hu B-S, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015 Jun 1;61(6):1870–9.

    Article  CAS  Google Scholar 

  14. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335–52.

    Article  Google Scholar 

  15. Govindarajan S, De Cock KM, Redeker AG. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatol Baltim Md. 1986 Aug;6(4):640–4.

    Article  CAS  Google Scholar 

  16. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560–99.

    Article  Google Scholar 

  17. Farci P, Anna NG. Current and future management of chronic hepatitis D. Gastroenterol Hepatol. 2018 Jun;14(6):342–51.

    Google Scholar 

  18. Samiullah S, Bikharam D, Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. 2012;18(40):5793–8.

    Article  CAS  Google Scholar 

  19. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27;364(4):322–31.

    Article  CAS  Google Scholar 

  20. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8.

    Article  CAS  Google Scholar 

  21. Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018 Apr 1;68:S3.

    Article  Google Scholar 

  22. Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018 Apr 1;67(4):1224–36.

    Article  CAS  Google Scholar 

  23. Yurdaydin C, Idilman R, Keskin O, Kalkan C, Karakaya MF, Caliskan A, et al. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study. J Hepatol. 2017 Jan 1;66(1):S33–4.

    Article  Google Scholar 

  24. Koh C, Surana P, Han T, Fryzek N, Kapuria D, Etzion O, et al. A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study. J Hepatol. 2017 Jan 1;66(1):S101–2.

    Article  Google Scholar 

  25. Wedemeyer H, Port K, Deterding K, Wranke A, Kirschner J, Bruno B, et al. A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study. J Hepatol. 2017 Jan 1;66(1):S24.

    Article  Google Scholar 

  26. Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One. 2015;10(11):e0140909.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loyola University Medical Center, 2160 S First Ave., Maywood, IL, 60153, USA

    Nayantara Orekondy & Eric R. Kallwitz

Authors
  1. Nayantara Orekondy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric R. Kallwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric R. Kallwitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orekondy, N., Kallwitz, E.R. A Brief Update on the Management of Hepatitis Delta. Curr Gastroenterol Rep 20, 60 (2018). https://doi.org/10.1007/s11894-018-0666-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-018-0666-1

Search

Navigation